Company Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA.
The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 1990 |
| IPO Date | May 3, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Howard Robin |
Contact Details
Address: 455 Mission Bay Boulevard South San Francisco, California 94158 United States | |
| Phone | 415 482 5300 |
| Website | nektar.com |
Stock Details
| Ticker Symbol | NKTR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000906709 |
| CUSIP Number | 640268306 |
| ISIN Number | US6402683063 |
| Employer ID | 94-3134940 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Howard W. Robin | Chief Executive Officer, President and Director |
| Sandra A. Gardiner | Interim Chief Financial Officer |
| Dr. Jonathan Zalevsky Ph.D. | Senior Vice President and Chief Research and Development Officer |
| Jason Barnard | Chief Accounting Officer |
| Robert Bacci | Chief People Officer and Head of Quality and Facilities |
| Jennifer Ruddock | Chief Business Officer |
| Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer |
| Dr. Ken Franke Ph.D. | Senior Vice President of Biologics Process Development and Manufacturing |
| Charleen Jue | Senior Vice President of Clinical Development Operations |
| Takahiro Miyazaki | Senior Vice President and Head of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2026 | ARS | Filing |
| Apr 24, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 24, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 23, 2026 | 8-K | Current Report |
| Apr 23, 2026 | 424B5 | Filing |
| Apr 20, 2026 | 424B5 | Filing |
| Apr 20, 2026 | 8-K | Current Report |
| Apr 20, 2026 | 8-K | Current Report |
| Apr 17, 2026 | SCHEDULE 13G | Filing |
| Mar 27, 2026 | SCHEDULE 13G/A | Filing |